Seneca Biopharma Inc.
https://senecabio.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Seneca Biopharma Inc.
Finance Watch: Four New VC Funds Provide $1.3bn For Biotech Start-Ups
Private Company Edition: Newpath Partners’ second fund totals $350m, Merck KGaA committed €600m to M Ventures, Eir Ventures raised €122.3m and Breakout Ventures has $112.5m. Recent financings were led by SOTIO ($317.5m), Odyssey ($218m), Avistone ($200m) and Acepodia ($109m).
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS
Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Leading BioSciences, Inc.
- Neuralstem, Inc.
- Palisade Bio, Inc.
- Suzhou Neuralstem Biopharmaceuticals